第 1 到 37 筆結果,共 37 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2020 | Landscape of mitochondria genome and clinical outcomes in stage 1 lung adenocarcinoma | Raghav L.; Chang Y.-H.; Hsu Y.-C.; Li Y.-C.; Chen C.-Y.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Chuang C.-Y.; Lee M.-H.; Wang C.-L.; HUEI-WEN CHEN ; SUNG-LIANG YU ; SHENG-FANG SU ; Yuan S.-S.; Chen J.J.W.; Ho S.-Y.; Li K.-C.; PAN-CHYR YANG ; Chang G.-C.; Chen H.-Y. | Cancers | 8 | 8 | |
2 | 2019 | High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients | Hsu K.-H.; Huang Y.-H.; Tseng J.-S.; Chen K.-C.; Ku W.-H.; KANG-YI SU ; Chen J.J.W.; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang T.-Y.; Chang G.-C. | Lung Cancer | 64 | 52 | |
3 | 2019 | Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis | Hung P.-F.; Hong, T.-M.; Chang C.-C.; Hung C.-L.; Hsu Y.-L.; YIH-LEONG CHANG ; CHEN-TU WU ; Chang G.-C.; NEI-LI CHAN ; SUNG-LIANG YU ; PAN-CHYR YANG ; SZU-HUA PAN | Journal of Experimental and Clinical Cancer Research | 20 | 19 | |
4 | 2019 | Tumor mutation burden and recurrent tumors in hereditary lung cancer | Hsu Y.-C.; Chang Y.-H.; Chang G.-C.; Ho B.-C.; Yuan S.-S.; Li Y.-C.; Zeng J.-W.; SUNG-LIANG YU ; Li K.-C.; PAN-CHYR YANG ; Chen H.-Y. | Cancer Medicine | 13 | 13 | |
5 | 2019 | The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan | Tseng C.-H.; Tsuang B.-J.; CHUN-JU CHIANG ; Ku K.-C.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; SUNG-LIANG YU ; WEN-CHUNG LEE ; Liu T.-W.; CHANG-CHUAN CHAN ; Chang G.-C. | Journal of Thoracic Oncology | 115 | 106 | |
6 | 2018 | Characteristics and Predictive Value of PD-L1 Status in Real-World NonSmall Cell Lung Cancer Patients | Tseng J.-S.; Yang T.-Y.; Wu C.-Y.; Ku W.-H.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Journal of Immunotherapy | 29 | 25 | |
7 | 2018 | Intercalated treatment following rebiopsy is associated with a shorter progression-free survival of osimertinib treatment | Tseng J.-S.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Cancer Research and Treatment | 5 | 5 | |
8 | 2018 | Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma | KANG-YI SU ; Tseng J.-S.; Liao K.-M.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; PAN-CHYR YANG ; SUNG-LIANG YU ; Chang G.-C. | PLoS ONE | 17 | 13 | |
9 | 2018 | FAM198B is associated with prolonged survival and inhibits metastasis in lung adenocarcinoma via blockage of ERK-Mediated MMP-1 expression | Hsu C.-Y.; Chang G.-C.; Chen Y.-J.; Hsu Y.-C.; Hsiao Y.-J.; KANG-YI SU ; Chen H.-Y.; Lin C.-Y.; JIN-SHING CHEN ; Chen Y.-J.; Hong Q.-S.; Ku W.-H.; Wu C.-Y.; Ho B.-C.; Chiang C.-C.; PAN-CHYR YANG ; SUNG-LIANG YU | Clinical Cancer Research | 20 | 20 | |
10 | 2017 | Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non–small cell lung cancer patients | SZU-HUA PAN ; KANG-YI SU ; Spiessens B.; Kusuma N.; Delahaye N.F.; Gruselle O.; Myo A.; de Creus A.; Louahed J.; Chang G.-C.; SUNG-LIANG YU ; PAN-CHYR YANG | Asia-Pacific Journal of Clinical Oncology | 13 | 14 | |
11 | 2016 | Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients | Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; SUNG-LIANG YU ; KANG-YI SU ; CHONG-JEN YU ; CHAO-CHI HO ; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; PAN-CHYR YANG ; Chen J.J.W.; Chang G.-C. | Oncotarget | 9 | 9 | |
12 | 2016 | SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma | Hsiao Y.-J.; KANG-YI SU ; Hsu Y.-C.; Chang G.-C.; JIN-SHING CHEN ; Chen H.-Y.; Hong Q.-S.; Hsu S.-C.; Kang P.-H.; Hsu C.-Y.; Ho B.-C.; Yang T.-H.; Wang C.-Y.; Jou Y.-S.; PAN-CHYR YANG ; SUNG-LIANG YU | Oncotarget | 23 | 23 | |
13 | 2016 | Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma | Su T.-J.; Ku W.-H.; Chen H.-Y.; Hsu Y.-C.; Hong Q.-S.; Chang G.-C.; SUNG-LIANG YU ; Chen J.J.W. | American Journal of Cancer Research | 22 | ||
14 | 2016 | Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice | KANG-YI SU ; JAU-TSUEN KAO ; Ho B.-C.; Chen H.-Y.; Chang G.-C.; CHAO-CHI HO ; SUNG-LIANG YU | Scientific Reports | 11 | 11 | |
15 | 2016 | JAG1 is associated with poor survival through inducing metastasis in lung cancer | Chang W.-H.; Ho B.-C.; Hsiao Y.-J.; JIN-SHING CHEN ; Yeh C.-H.; Chen H.-Y.; Chang G.-C.; KANG-YI SU ; SUNG-LIANG YU | PLoS ONE | 30 | 29 | |
16 | 2016 | The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M | Tseng J.-S.; KANG-YI SU ; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen H.-Y.; Tsai C.-R.; SUNG-LIANG YU ; Chang G.-C. | Oncotarget | 24 | 23 | |
17 | 2016 | Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients | Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; KANG-YI SU ; Chen H.-Y.; Chang C.-S.; Chen J.J.W.; SUNG-LIANG YU ; HUEI-WEN CHEN ; Yang T.-Y.; Chang G.-C. | Journal of Thoracic Disease | 2 | 2 | |
18 | 2016 | HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms | Chen C.-H.; Chang W.-H.; KANG-YI SU ; Ku W.-H.; Chang G.-C.; Hong Q.-S.; Hsiao Y.-J.; Chen H.-C.; Chen H.-Y.; Wu R.; PAN-CHYR YANG ; Chen J.J.W.; SUNG-LIANG YU | Oncogene | 21 | 21 | |
19 | 2016 | Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition | Lin S.-Y.; Lee Y.-X.; SUNG-LIANG YU ; Chang G.-C.; Chen J.J.W. | Oncotarget | 7 | 7 | |
20 | 2016 | Molecular gene signature and prognosis of non-small cell lung cancer | Huang P.; Cheng C.-L.; Chang Y.-H.; Liu C.-H.; Hsu Y.-C.; JIN-SHING CHEN ; Chang G.-C.; Ho B.-C.; KANG-YI SU ; Chen H.-Y.; SUNG-LIANG YU | Oncotarget | 17 | 16 | |
21 | 2016 | EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma | Chen H.-Y.; Liu C.-H.; Chang Y.-H.; SUNG-LIANG YU ; Ho B.C.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Chang C.-S.; Li Y.-C.; Li K.-C.; Chang G.-C.; PAN-CHYR YANG | Oncotarget | 14 | 16 | |
22 | 2015 | Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways | Lai Y.-H.; Chen M.-H.; Lin S.-Y.; Lin S.-Y.; Wong Y.-H.; SUNG-LIANG YU ; HUEI-WEN CHEN ; CHIH-HSIN YANG ; Chang G.-C.; Chen J.J.W. | Oncotarget | 10 | 8 | |
23 | 2015 | HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma | Wang C.-C.; KANG-YI SU ; Chen H.-Y.; Chang S.-Y.; Shen C.-F.; Hsieh C.-H.; Hong Q.-S.; Chiang C.-C.; Chang G.-C.; SUNG-LIANG YU ; Chen J.J.W. | PLoS ONE | 38 | 32 | |
24 | 2015 | Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan | Hsu K.-H.; CHAO-CHI HO ; Hsia T.-C.; Tseng J.-S.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Chang G.-C. | PLoS ONE | 98 | 92 | |
25 | 2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 13 | 12 | |
26 | 2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |
27 | 2014 | Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling | Chen W.-J.; CHAO-CHI HO ; YIH-LEONG CHANG ; Chen H.-Y.; Lin C.-A.; THAI-YEN LING ; SUNG-LIANG YU ; Yuan S.-S.; Louisa Chen Y.-J.; Lin C.-Y.; SZU-HUA PAN ; HAN-YI E. CHOU ; Chang G.-C.; Chu W.-C.; Lee Y.-M.; Lee J.-Y.; Lee P.-J.; Li K.-C.; HUEI-WEN CHEN ; PAN-CHYR YANG | Nature Communications | 302 | 278 | |
28 | 2014 | Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer | Chen C.-C.; Chen H.-Y.; KANG-YI SU ; Hong Q.-S.; BO-SHIUN YAN ; Chen C.-H.; SZU-HUA PAN ; YIH-LEONG CHANG ; Wang C.-J.; Hung P.-F.; Yuan S.; Chang G.-C.; Chen J.J.W.; PAN-CHYR YANG ; YA-CHIEN YANG ; SUNG-LIANG YU | American Journal of Respiratory and Critical Care Medicine | 30 | 33 | |
29 | 2012 | Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer | KANG-YI SU ; Chen H.-Y.; Li K.-C.; Kuo M.-L.; CHIH-HSIN YANG ; Chan W.-K.; Ho B.-C.; Chang G.-C.; JIN-YUAN SHIH ; SUNG-LIANG YU ; PAN-CHYR YANG | Journal of Clinical Oncology | 464 | 428 | |
30 | 2011 | Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations | Yuan S.; SUNG-LIANG YU ; Chen H.-Y.; Hsu Y.-C.; KANG-YI SU ; HUEI-WEN CHEN ; Chen C.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 28 | 26 | |
31 | 2011 | Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy | Lee J.-Y.; Lee Y.-M.; Chang G.-C.; SUNG-LIANG YU ; Hsieh W.-Y.; Chen J.J.W.; HUEI-WEN CHEN ; PAN-CHYR YANG | PLoS ONE | 111 | 86 | |
32 | 2010 | HLJ1 is a novel caspase-3 substrate and its expression enhances UV-induced apoptosis in non-small cell lung carcinoma | Lin S.-Y.; Hsueh C.-M.; SUNG-LIANG YU ; Su C.-C.; Shum W.-Y.; Yeh K.-C.; Chang G.-C.; Chen J.J.W. | Nucleic Acids Research | 27 | 25 | |
33 | 2010 | Tumor suppressor HLJ1 binds and functionally alters nucleophosmin via activating enhancer binding protein 2α complex formation | Chang T.-P.; SUNG-LIANG YU ; Lin S.-Y.; Hsiao Y.-J.; Chang G.-C.; PAN-CHYR YANG ; Chen J.J.W. | Cancer Research | 20 | 21 | |
34 | 2009 | A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer | Hsu Y.-C.; Yuan S.-S.; Chen H.-Y.; SUNG-LIANG YU ; Liu C.-H.; Hsu P.-Y.; Wu G.; Lin C.-H.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Clinical Cancer Research | 47 | 43 | |
35 | 2009 | Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma | Chao Y.-C.; SZU-HUA PAN ; Yang S.-C.; SUNG-LIANG YU ; Che T.-F.; CHUNG-WU LIN ; Tsai M.-S.; Chang G.-C.; Wu C.-H.; Wu Y.-Y.; Lee Y.-C.; Hong T.-M.; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 153 | 142 | |
36 | 2008 | MicroRNA Signature Predicts Survival and Relapse in Lung Cancer | SUNG-LIANG YU ; HSUAN-YU CHEN; Chang G.-C.; Chen C.-Y.; HUEI-WEN CHEN ; Singh S.; Cheng C.-L.; CHONG-JEN YU ; Lee Y.-C.; Chen H.-S.; Su T.-J.; Chiang C.-C.; Li H.-N.; Hong Q.-S.; Su H.-Y.; Chen C.-C.; Chen, W.-J.; Liu C.-C.; Chan W.-K.; WEI J. CHEN ; Li K.-C.; Chen J.J.W.; PAN-CHYR YANG | Cancer Cell | 725 | 672 | |
37 | 2007 | A five-gene signature and clinical outcome in non-small-cell lung cancer | Chen H.-Y.; SUNG-LIANG YU ; Chen C.-H.; Chang G.-C.; Chen C.-Y.; ANG YUAN ; Cheng C.-L.; Wang C.-H.; Terng H.-J.; Kao S.-F.; Chan W.-K.; Li H.-N.; Liu C.-C.; Singh S.; WEI J. CHEN ; Chen J.J.W.; PAN-CHYR YANG | New England Journal of Medicine | 794 | 735 |